热门出版物 - 学术资源搜索

h5 指数:120
h5 中位数:187

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#2 Hematology
#14 Oncology

标题/作者	引用次数	年份
The biology and role of CD44 in cancer progression: therapeutic implications C Chen, S Zhao, A Karnad, JW Freeman Journal of Hematology & Oncology 11, 1-23	868	2018
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications Y Lin, J Xu, H Lan Journal of Hematology & Oncology 12 (1), 1-16	799	2019
Ferroptosis, a new form of cell death: opportunities and challenges in cancer Y Mou, J Wang, J Wu, D He, C Zhang, C Duan, B Li Journal of Hematology & Oncology 12 (1), 1-16	763	2019
Next generation of immune checkpoint therapy in cancer: new developments and challenges JA Marin-Acevedo, B Dholaria, AE Soyano, KL Knutson, S Chumsri, ... Journal of Hematology & Oncology 11, 1-20	626	2018
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 S Zhang, Y Liu, X Wang, L Yang, H Li, Y Wang, M Liu, X Zhao, Y Xie, ... Journal of Hematology & Oncology 13 (1), 1-22	606	2020
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity R Tang, J Xu, B Zhang, J Liu, C Liang, J Hua, Q Meng, X Yu, S Shi Journal of Hematology & Oncology 13, 1-18	581	2020
Targeting mTOR for cancer therapy H Hua, Q Kong, H Zhang, J Wang, T Luo, Y Jiang Journal of Hematology & Oncology 12 (1), 1-19	548	2019
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy T Liu, C Han, S Wang, P Fang, Z Ma, L Xu, R Yin Journal of Hematology & Oncology 12 (1), 1-15	536	2019
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics A Akinleye, Z Rasool Journal of Hematology & Oncology 12 (1), 92	534	2019
Targeting the Wnt/β-catenin signaling pathway in cancer Y Zhang, X Wang Journal of Hematology & Oncology 13, 1-16	501	2020
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy P Zhao, L Li, X Jiang, Q Li Journal of Hematology & Oncology 12 (1), 1-14	391	2019
EZH2: a novel target for cancer treatment R Duan, W Du, W Guo Journal of Hematology & Oncology 13 (1), 1-12	388	2020
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma WH Zhao, J Liu, BY Wang, YX Chen, XM Cao, Y Yang, YL Zhang, ... Journal of Hematology & Oncology 11 (1), 1-8	386	2018
Role of platelets and platelet receptors in cancer metastasis M Schlesinger Journal of Hematology & Oncology 11 (1), 1-15	374	2018
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel D Porter, N Frey, PA Wood, Y Weng, SA Grupp Journal of Hematology & Oncology 11, 1-12	351	2018
The interplay between m6A RNA methylation and noncoding RNA in cancer S Ma, C Chen, X Ji, J Liu, Q Zhou, G Wang, W Yuan, Q Kan, Z Sun Journal of Hematology & Oncology 12 (1), 1-15	331	2019
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development G Shen, F Zheng, D Ren, F Du, Q Dong, Z Wang, F Zhao, R Ahmad, ... Journal of Hematology & Oncology 11 (1), 1-11	319	2018
m 6 A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis D Jin, J Guo, Y Wu, J Du, L Yang, X Wang, W Di, B Hu, J An, L Kong, ... Journal of Hematology & Oncology 12, 1-22	312	2019
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors Y Liu, Y Dong, L Kong, F Shi, H Zhu, J Yu Journal of Hematology & Oncology 11 (1), 1-15	299	2018
Tumor neoantigens: from basic research to clinical applications T Jiang, T Shi, H Zhang, J Hu, Y Song, J Wei, S Ren, C Zhou Journal of Hematology & Oncology 12, 1-13	279	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。